Citations

Showing 10 of 108083 citations.

A63 TRENDS AND OUTCOMES OF LIVER DISEASE HOSPITALIZATIONS DURING THE CORONAVIRUS PANDEMIC IN THE UNITED STATES: A NATIONWIDE POPULATION-LEVEL ANALYSIS
Sedarous, Mary , Adekunle, Ayooluwatomiwa D. , Babajide, O, Okafor, Philip N. , Sedarous, Mary , Youssef, M, Babajide, Oyedotun , Rubens, Muni

Mayo Clinic

Journal of the Canadian Association of Gastroenterology | March 7, 2023 | Volume: 6 | Issue: Supplement_1 | Pages: 34-35

10.1093/jcag/gwac036.063 Get It

Abstract Background The impact of the Coronavirus disease-2019 (COVID-19) pandemic on patients with liver disease is not well described at the population level in the United States. Purpose We used the largest, nationwide inpatient dataset to describe inpatient liver disease outcomes in the United States during the first year of the pandemic (2020) using 2018 and 2019 as comparator years. Method Using the National Inpatient Sample (2018-2020), we explored year-to-year and 2020 month-to-month trends in hospitalizations, length of stay, and inpatient mortality for liver-related indications including compensated cirrhosis, decompensated cirrhosis, alcohol-associated liver disease (ALD), alcohol-associated hepatitis (AH), hepatocellular carcinoma (HCC), and variceal upper gastrointestinal bleeding (VUGIB) using regression modeling. We also looked at the impact of the COVID-19 pandemic on liver transplantation rates. A p-value <0.05 was considered statistically significant. Result(s) Hospitalizations for both compensated and decompensated cirrhosis decreased in 2020 compared to 2019 (relative change [RC] of 1.5%, p <0.001, Table 1). Interestingly, hospitalizations for ALD and AH increased in 2020 compared to pre-pandemic years (ALD RC=15.5% and AH RC 17.0%; p<0.001). Despite the decrease in cirrhosis hospitalizations in 2020, all-cause inpatient mortality among patients with compensated cirrhosis increased from 30,135 in 2019 to 35,220 in 2020 (p<0.001) and from 22,850 in 2019 to 26,390 in 2020 among patients with decompensated cirrhosis (p<0.001). This was accompanied by a 27.8% increase in mortality for ALD (p=0.004) in comparison to pre-pandemic years. Corresponding to the peaks of the pandemic, we observed the fewest cirrhosis hospitalizations in April and December 2020 (Table 2), however, these months had the highest observed mortality rates (p-trend ≤ 0.004). Reassuringly, liver transplantation rates were not significantly impacted by the COVID-19 pandemic (p=0.51). Image Conclusion(s) Cirrhosis hospitalizations, in general, decreased in 2020 compared to pre-pandemic years but were associated with higher all-cause mortality rates particularly in the peak months of the COVID-19 pandemic (April and December 2020) possibly reflecting COVID-19 specific mortality. Alcoholic liver disease admissions also increased during the pandemic while liver transplantation rates were not significant impacted. Please acknowledge all funding agencies by checking the applicable boxes below None Disclosure of Interest None Declared
Artificial Intelligence in Breast Imaging: Challenges of Integration Into Clinical Practice
Ozcan, B. Bersu , Patel, Bhavika , Banerjee, Imon , Patel, Bhavika K , Dogan, Basak E , Banerjee, Imon

Mayo Clinic

Journal of Breast Imaging | March 7, 2023 | Volume: 5 | Issue: 3 | Pages: 248-257

10.1093/jbi/wbad007 | PMID 38416888 Get It

Abstract Artificial intelligence (AI) in breast imaging is a rapidly developing field with promising results. Despite the large number of recent publications in this field, unanswered questions have led to limited implementation of AI into daily clinical practice for breast radiologists. This paper provides an overview of the key limitations of AI in breast imaging including, but not limited to, limited numbers of FDA-approved algorithms and annotated data sets with histologic ground truth; concerns surrounding data privacy, security, algorithm transparency, and bias; and ethical issues. Ultimately, the successful implementation of AI into clinical care will require thoughtful action to address these challenges, transparency, and sharing of AI implementation workflows, limitations, and performance metrics within the breast imaging community and other end-users.
Characterizing the wireless data transmission of biosignals within a health-care environment
Childress, Madison L. , Bruhnke, Russell E. , Frandsen, Clint R., Benscoter, Mark A.

Mayo Clinic

IEEE Potentials | March 7, 2023 | Volume: 42 | Issue: 2 | Pages: 4-10

10.1109/mpot.2019.2911319 Get It

Reporting Essentials for DElirium bioMarker Studies (REDEEMS): Explanation and Elaboration
Amgarth‐Duff, Ingrid , Hosie, Annmarie , Olofsson, Birgitta, Steiner, Luzius A. , Vasunilashorn, Sarinnapha M. , Agar, Meera , Caplan, Gideon A. , Adamis, Dimitrios , Watne, Leiv Otto , Cunningham, Colm M. , Oh, Esther S , Wang, Sophia , Lindroth, Heidi , Sanders, Robert D. , Olofsson, Birgitta, Girard, Timothy D.

Mayo Clinic

Delirium | March 7, 2023 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.56392/001c.57389 Get It

Despite many studies of potential delirium biomarkers, delirium pathophysiology remains unclear. Evidence shows that the quality of reporting delirium biomarker studies is sub-optimal. Better reporting of delirium biomarker studies is needed to understand delirium pathophysiology better. To improve robustness, transparency and uniformity of delirium biomarker study reports, the REDEEMS (Reporting Essentials for DElirium bioMarker Studies) guideline was developed by an international group of delirium researchers through a three-stage process, including a systematic review, a three-round Delphi study, and a follow-up consensus meeting. This process resulted in a 9-item guideline to inform delirium fluid biomarker studies. To enhance implementation of the REDEEMS guideline, this Explanation and Elaboration paper provides a detailed explanation of each item. We anticipate that the REDEEMS guideline will help to accelerate our understanding of delirium pathophysiology by improving the reporting of delirium biomarker research and, consequently the capacity to synthesise results across studies.
Implementation of genomic medicine for rare disease in a tertiary healthcare system: Mayo Clinic Program for Rare and Undiagnosed Diseases (PRaUD)
Kemppainen, Jennifer L., Vitek, Carolyn R. Rohrer , Whalen, Denise A., Kolbert, Kayla J., Sikkink, Kaitlin J. , Kroc, Sarah A., Kruisselbrink, Teresa , Shupe, Gabrielle F., Knudson, Alyssa K., Burke, Elizabeth , Loftus, Elle C., Bandel, Lorelei A. , Prochnow, Carri A., Mulvihill, Lindsay A., Thomas, Brittany C. , Gamble, Dale M., Graddy, Courtney B., Garzon, Giovanna G. Moreno, Ekpoh, Idara U., Porquera, Eva M. Carmona, Hogan, Marie C. , Ters, Mireille El , Davis, III John M., Vella, Adrian, Kumar, Seema , Creo, Ana L. , Lteif, Aida, Pittock, Siobhán T. , Tebben, Peter J. , Abate, Ejigayehu G., Joshi, Avni Y. , Ristagno, Elizabeth H. , Patnaik, Mrinal S., Sabrowsky, Sonia M., Wierenga, Klaas J. , Keddis, Mira T. , Samadder, N. Jewel , Presutti, R. John , Stephens, Michael C., Roberts, Lewis R. , Faubion, William A. , Driscoll, Sherilyn W. , Selcen, Duygu , Jackson, Lauren , Ortega, Victor E. , Anderson, Sarah , Aoudia, Stacy L., Klee, Eric W. , McAllister, Tammy M., Carmona, Eva M. , Carmona, Eva M , Roberts, Lewis R , Presutti, Richard J , Tebben, Peter , Hogan, Marie C , Vairo, Filippo Pinto e , Burke, Elizabeth M., Fervenza, Fernando C. , Warrington, Kenneth J. , Koster, Matthew J. , Orandi, Amir B. , Basiaga, Matthew L. , Patnaik, Mrinal S., Schimmenti, Lisa A. , Dhamija, Radhika , Robinson, Steven I. , Wong‐Kisiel, Lily C. , Flanagan, Eoin P. , Ramanan, Vijay K. , Mauermann, Michelle L. , Lazaridis, Konstantinos N.

Mayo Clinic

No container title available | March 7, 2023 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-2617916/v1 Get It

Abstract Background In the United States, rare disease (RD) is defined as a condition that affects fewer than 200,000 individuals. Collectively, RD affects an estimated 30 million Americans. A significant portion of RD has an underlying genetic cause; however, this may go undiagnosed. To better serve these patients, the Mayo Clinic Program for Rare and Undiagnosed Diseases (PRaUD) was created under the auspices of the Center for Individualized Medicine (CIM) aiming to integrate genomics into subspecialty practice including targeted genetic testing, research, and education. Methods Patients were identified by subspecialty healthcare providers from 11 clinical divisions/departments. Targeted multi-gene panels or custom exome/genome-based panels were utilized. To support the goals of PRaUD, a new clinical service model, the Genetic Testing and Counseling (GTAC) unit, was established to improve access and increase efficiency for genetic test facilitation. The GTAC unit includes genetic counselors, genetic counseling assistants, genetic nurses, and a medical geneticist. Patients receive abbreviated point-of-care genetic counseling and testing through a partnership with subspecialty providers. Results Implementation of PRaUD began in 2018 and GTAC unit launched in 2020 to support program expansion. Currently, 29 RD clinical indications are included in 11 specialty divisions/departments with over 142 referring providers. To date, 1,152 patients have been evaluated with an overall solve rate of 14.1% and as high as 66.7% depending on the phenotype. Noteworthy, 42.7% of the solved or likely solved patients underwent changes in medical management and outcome based on genetic test results. Conclusion Implementation of PRaUD and GTAC have enabled subspecialty practices advance expertise in RD where genetic counselors have not historically been embedded in practice. Democratizing access to genetic testing and counseling can broaden the reach of patients with RD and increase the diagnostic yield of such indications leading to better medical management as well as expanding research opportunities.
Analog, graded choices in the human brain
Kubanek, Jan , Xie, Tao , Adamek, Markus , Adamo, Matthew A. , Ritaccio, Anthony L. , Cho, Hohyun , Willie, Jon T , Brunner, Peter

Mayo Clinic

No container title available | March 7, 2023 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-2635814/v1 Get It

Abstract Decision-makers objectively commit to a definitive choice, yet at the subjective level, human decisions appear to be associated with a degree of certainty. Whether decisions are definitive—concluding in all-or-none choices, or whether the underlying representations are graded, has been unclear. To address this issue, we recorded neural signals directly from the brain while naive human subjects made perceptual decisions. The recordings revealed that each individual’s decisions formed within broadband gamma activity. The gamma activity was graded by decision evidence. Crucially, this analog, grading effect prevailed beyond the time of choice, instead of assuming a switch-like command. The effect was strongest in parietal and premotor cortex, brain regions traditionally implicated in decision-making. These data provide neural evidence for a graded nature of the decision process.
Hereditary transthyretin amyloidosis presenting with spontaneous periorbital purpura: a case report
Jhawar, Nikita , Nakhleh, Raouf E. , Lyle, Melissa , Nakhleh, Raouf, Jhawar, N , Reynolds, Jordan

Mayo Clinic

European Heart Journal - Case Reports | March 7, 2023 | Volume: 7 | Issue: 3 | Pages: No page available

10.1093/ehjcr/ytad108 | PMID 37006801 Get It

AbstractBackgroundAmyloidosis is a systemic disorder of abnormal protein folding and deposition resulting in a range of symptoms including neuropathy, heart failure, renal disease, and dermatologic findings. The two most common types of amyloidosis that affect the heart are transthyretin (ATTR) amyloidosis and light chain (AL) amyloidosis, which vary in clinical presentation. Skin findings such as periorbital purpura are considered more specific for AL amyloidosis. However, there are rare cases of ATTR amyloidosis causing the same dermatologic findings.Case SummaryA 69-year-old female presented for evaluation of amyloidosis after cardiac imaging done at the time of a recent atrial fibrillation ablation showed signs of infiltrative disease. On examination, she had periorbital purpura which she reportedly had for years without receiving a diagnosis, as well as macroglossia with teeth indentation. These exam findings, in addition to her transthoracic echocardiogram showing apical sparing, are typically considered characteristic of AL amyloidosis. Subsequent workup revealed the presence of hereditary ATTR (hATTR) amyloidosis with a heterozygous pathogenic variant in the TTR gene producing the p.Thr80Ala mutation.ConclusionSpontaneous periorbital purpura is thought to be pathognomonic for AL amyloidosis. However, we describe a case of hereditary ATTR amyloidosis with the Thr80Ala TTR genetic variant presenting initially with periorbital purpura, the first case documented in the literature to our knowledge.
Identification, Measurement, and Assessment of the Clinical Utility of Human Pancreatic Polypeptide by Liquid Chromatography–Tandem Mass Spectrometry
Maus, Anthony , Fatica, Erica M. , Larson, Bethany J., Grebe, Stefan K. , Maus, Anthony D , Taylor, Robert, Larson, Bethany J., Algeciras‐Schimnich, Alicia , Singh, Ravinder J.

Mayo Clinic

Journal of Proteome Research | March 7, 2023 | Volume: 22 | Issue: 4 | Pages: 1322-1330

10.1021/acs.jproteome.2c00829 | PMID 36880754 Get It

Community-Onset Bacterial Coinfection in Children Critically Ill With Severe Acute Respiratory Syndrome Coronavirus 2 Infection
酒井, 忠雄, Nakamura, Mari M, Young, Cameron C, Newhams, Margaret M, Halasa, Natasha B, Reed, J Nelson, Fitzgerald, Julie C, Spinella, Philip C, Soma, Vijaya L, Walker, Tracie C, Loftis, Laura L, Maddux, Aline B, Kong, Michele, Rowan, Courtney M, Hobbs, Charlotte V, Schuster, Jennifer E, Riggs, Becky J, McLaughlin, Gwenn E, Michelson, Kelly N, Hall, Mark W, Babbitt, Christopher J, Cvijanovich, Natalie Z, Zinter, Matt S, Maamari, Mia, Schwarz, Adam J, Singh, Aalok R, Flori, Heidi R, Gertz, Shira J, Staat, Mary A, Giuliano, John S, Hymes, Saul R, Clouser, Katharine N, McGuire, John, Carroll, Christopher L, Thomas, Neal J, Levy, Emily R, Randolph, Adrienne G, Randolph, Adrienne G. , Spinella, Philip C. , Levy, Emily R. , Staat, Mary Allen , Young, Cameron C. , McGuire, John K. , Gertz, Shira J. , Kong, Michele , Zinter, Matt S. , Moffitt, Kristin , Malloch, Lacy , Moffitt, Kristin L , Young, Cameron C , Hobbs, Charlotte V , Randolph, Adrienne G , Levy, Emily R , Spinella, Philip C , Kong, Michele , Staat, Mary A , Gertz, Shira J , Nakamura, Mari M, Newhams, Margaret M, Halasa, Natasha B, Reed, J Nelson, Fitzgerald, Julie C, Spinella, Philip C, Soma, Vijaya L, Walker, Tracie C, Loftis, Laura L, Maddux, Aline B, Kong, Michele, Rowan, Courtney M, Schuster, Jennifer E, Riggs, Becky J, McLaughlin, Gwenn E, Michelson, Kelly N, Hall, Mark W, Babbitt, Christopher J, Cvijanovich, Natalie Z, Zinter, Matt S, Maamari, Mia, Schwarz, Adam J, Singh, Aalok R, Flori, Heidi R, Gertz, Shira J, Staat, Mary A, Giuliano, John S, Hymes, Saul R, Clouser, Katharine N, McGuire, John, Carroll, Christopher L, Thomas, Neal J, Levy, Emily R

Mayo Clinic

Open Forum Infectious Diseases | March 7, 2023 | Volume: 10 | Issue: 3 | Pages: No page available

10.1093/ofid/ofad122 | PMID 36968962 Get It

AbstractBackgroundCommunity-onset bacterial coinfection in adults hospitalized with coronavirus disease 2019 (COVID-19) is reportedly uncommon, though empiric antibiotic use has been high. However, data regarding empiric antibiotic use and bacterial coinfection in children with critical illness from COVID-19 are scarce.MethodsWe evaluated children and adolescents aged <19 years admitted to a pediatric intensive care or high-acuity unit for COVID-19 between March and December 2020. Based on qualifying microbiology results from the first 3 days of admission, we adjudicated whether patients had community-onset bacterial coinfection. We compared demographic and clinical characteristics of those who did and did not (1) receive antibiotics and (2) have bacterial coinfection early in admission. Using Poisson regression models, we assessed factors associated with these outcomes.ResultsOf the 532 patients, 63.3% received empiric antibiotics, but only 7.1% had bacterial coinfection, and only 3.0% had respiratory bacterial coinfection. In multivariable analyses, empiric antibiotics were more likely to be prescribed for immunocompromised patients (adjusted relative risk [aRR], 1.34 [95% confidence interval {CI}, 1.01–1.79]), those requiring any respiratory support except mechanical ventilation (aRR, 1.41 [95% CI, 1.05–1.90]), or those requiring invasive mechanical ventilation (aRR, 1.83 [95% CI, 1.36–2.47]) (compared with no respiratory support). The presence of a pulmonary comorbidity other than asthma (aRR, 2.31 [95% CI, 1.15–4.62]) was associated with bacterial coinfection.ConclusionsCommunity-onset bacterial coinfection in children with critical COVID-19 is infrequent, but empiric antibiotics are commonly prescribed. These findings inform antimicrobial use and support rapid de-escalation when evaluation shows coinfection is unlikely.